# Healthcor Management

> Healthcor Management is a VC fund backing Health Care and Biotechnology. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Charleston, United States
- Total investments: 24
- Last investment: Mar 2025
- Lead investor: 13%
- Fund size: $101M
- Last fund: Mar 2014
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/healthcor-management-l-p-/
- X (Twitter): https://twitter.com/healthcorptnrs
- Website: http://healthcorpartners.com

Healthcor Management is a VC fund in Charleston focused on Health Care and Biotechnology. HealthCor Partners Management, L.P. ("HealthCor Partners"), is a registered investment advisor with the U.S. Securities and Exchange Commission (the “SEC”). Together with its affiliate, HealthCor Partners has approximately $365 million of capital commitments dedicated to private equity investments. HealthCor Partners invests primarily ingrowth equity and later stage developmental companies across all sectors of the healthcare and life sciences industry.

## Contacts

5 contacts available for Healthcor Management. Shizune tracks 2 team members at Healthcor Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/healthcor-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 15 | 63% |
| Biotechnology | 10 | 42% |
| Medical | 9 | 38% |
| Medical Device | 7 | 29% |
| Health Diagnostics | 5 | 21% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 5 | 21% |
| Series B | 4 | 17% |
| Series C | 3 | 13% |
| Seed | 2 | 8% |
| Series D | 2 | 8% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 67% |
| Canada | 1 | 4% |
| France | 1 | 4% |
| United Kingdom | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jeffrey C. Lightcap | Managing Partner | 2 | — |
| Michael Mashaal | Senior Managing Director | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Heartflow | HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on bloodflow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe and Japan. For more information, visit www.heartflow.com. | $98M | Convertible Note | Mar 26, 2025 |  |
| Heartflow | HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on bloodflow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe and Japan. For more information, visit www.heartflow.com. | $215M | Series F | Apr 06, 2023 |  |
| Karyopharm Therapeutics | Karyopharm Therapeutics is a biopharmaceutical company focusing on the development of novel drugs for the treatment of cancer, inflammation and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g.FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and to evaluate them in subsequent human clinical studies. | $165M | Post-IPO Equity | Dec 05, 2022 |  |
| Mineralys Therapeutics | Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. | $118M | Series B | Jun 08, 2022 |  |
| DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $35M | Series C | Jan 04, 2022 |  |
| Acrivon Therapeutics | Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethalcontexts. The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. | $100M | Series B | Nov 11, 2021 |  |
| Imperative Care | Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $260M | Series D | Jul 15, 2021 |  |
| Ikena Oncology | Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signalingpathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs. | $120M | Series B | Jan 05, 2021 |  |
| Claret Medical | Claret Medical, Inc. develops a series of cerebral vascular protection systems for transcatheter aortic valve implantation, surgical, and other interventional procedures. The company’s products include Claret Medical Montage, a dual filter system and percutaneously delivered embolic protection device to capture and remove debris disloged duringvascular procedures; and small (6F) catheters that are inserted into the patient's right arm to protect the patient’s brain during interventional procedures where embolic debris might be released. It offers its products for use as an embolic protection system to capture and remove embolic material (thrombus/debris) that may enter the cerebral vascular system during endovascular procedures. The company was incorporated in 2009 and is based in Santa Rosa, California. | $14.5M | Series C | Oct 23, 2017 |  |
| PreemaTEX | PreemaTEX is the developer of an innovative, high value diagnostic tests focused on assessing a woman’s risk for preterm delivery early in pregnancy. |  | Seed | Oct 01, 2015 |  |

10 of 24 investments shown.

## Co-investors
- [U.S. Venture Partners](https://shizune.co/investors/profile/us-venture-partners) — VC Fund, 5 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 3 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 3 deals together
- [Baillie Gifford](https://shizune.co/investors/profile/baillie-gifford) — VC Fund, 2 deals together
- [Capricorn Investment Group](https://shizune.co/investors/profile/capricorn-investment-group) — VC Fund, 2 deals together
- Catalys Pacific — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Healthcor Management invest in?

Healthcor Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Funding Round and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Healthcor Management?

Public channels for Healthcor Management include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Healthcor Management?

The team at Healthcor Management includes Jeffrey C. Lightcap (Managing Partner) and Michael Mashaal (Senior Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co